Cagent Vascular
WAYNE, Pennsylvania, United States · Healthcare, Health Care
Cagent Vascular has developed and commercialized its novel angioplasty balloon with Serration Technology to treat blocked arteries in the leg or Peripheral Artery Disease (PAD) and Chronic Limb Threatening Ischemia (CLTI). The Serranator PTA Serration Balloon Catheter is the first and only angioplasty balloon with serration technology.
Key facts
- Headquarters
- WAYNE, Pennsylvania, United States
- Employees
- Unknown
- Industries
- Healthcare, Health Care
- Status
- Private
- Website
- cagentvascular.com
- Company page
Recent activity at Cagent Vascular
- : Cagent Vascular closes an oversubscribed $41M Series D financing to advance its Serranator® SONIC IVL System for clinical launch and coronary program development.
- : Cagent Vascular and 3comma Medical Announce Strategic Partnership to Expand International Distribution of Serranator Product Family
- : Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Lead Commercial Strategy
- : Cagent Vascular Inc. received $15 million in growth capital from Trinity Capital Inc. to enhance its innovative vascular treatment technologies.
- : Cagent Vascular, Inc. launches the POINT FORCE Registry to evaluate the safety and efficacy of the Serranator® PTA Serration Balloon Catheter.
- : Cagent Vascular Appoints Brian Walsh as Chief Executive Officer
- : Cagent secures funding to expand portfolio of angioplasty technology
- : Cagent Vascular Raises $30 Million Series C Financing
- : Cagent Vascular
- : Cagent Vascular
Cagent Vascular funding history
| Date | Round | Amount |
|---|---|---|
| May 2026 | Series D | $41.0M |
| Feb 2025 | Funding Round | $15.0M |
| Feb 2024 | Series C | $30.0M |
| Feb 2024 | Series C | $30.0M |
| Feb 2024 | Venture | $28.7M |
Leadership
- Carol Burns, Executive Officer, Director
- Dennis McGrath, Executive Officer, Director
- Mike Markert, Director
- Peter Schneider, Director
- Fred Lampropoulos, Director
- Brian Walsh, Director
- Marc-Andre Marcotte, Director
- Robert Giasolli, Director
Verified email and direct lines for Cagent Vascular’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Cagent Vascular files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Cagent Vascular in the news
- Saving Limbs Where Others Stop: Cagent Vascular Announces Landmark Peer-Reviewed Data Demonstrating Safety and Efficacy of Serration Remodeling Therapy™ in the Most Challenging Arteries Below-the-Ankle - Business Wire (Apr 28, 2026)
- Cagent Vascular Expands Serranator Product Line with Launch of 7.0 mm and 8.0 mm Sizes - Business Wire (Oct 07, 2025)
Companies similar to Cagent Vascular
- eHealth · Healthcare, Health Care
- IRulya Therapeutics Inc. · Healthcare, Health Care
- Immuneering · Healthcare, Health Care
- Oruka Therapeutics · Healthcare, Health Care
- Beam Therapeutics Inc. · Healthcare, Health Care
About Cagent Vascular: questions and answers
What does Cagent Vascular do?
Cagent Vascular has developed and commercialized its novel angioplasty balloon with Serration Technology to treat blocked arteries in the leg or Peripheral Artery Disease (PAD) and Chronic Limb Threatening Ischemia (CLTI). The Serranator PTA Serration Balloon Catheter is the first and only angioplasty balloon with serration technology.
Where is Cagent Vascular headquartered?
Cagent Vascular is headquartered in WAYNE, Pennsylvania, United States.
Has Cagent Vascular raised funding?
Yes. Fundz has recorded 5 funding events for Cagent Vascular. The most recent, Series D of $41.0M, was in May 2026.
What is the latest news on Cagent Vascular?
On May 19, 2026, Cagent Vascular closes an oversubscribed $41M Series D financing to advance its Serranator® SONIC IVL System for clinical launch and coronary program development.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy